19239-Lung Cancer-NA-445

Lung Cancer

CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

  • Details

ClinicalTrials.gov ID: NCT04265534
Diagnosis Type: NA
USOR Number: 19239

  • Address

3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.